Wr-Crcn, LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$53,863	3
2024	Research	$22,863	1
2023	Research	$306,772	5
2022	Research	$358,849	12
2021	Research	$12,738	2
2020	Research	$68,519	1

Breakdown

Who paid Research payments · program years 2020–2025

Emergent BioSolutions Inc. $409,783 16 payments
Merck Sharp & Dohme Corporation $341,065 6 payments
Becton, Dickinson and Company $72,756 2 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $268,682 10 payments
A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older $264,339 2 payments
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 $132,601 5 payments
Veritor Antigen Assay $72,756 2 payments
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $33,804 1 payment
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $22,863 1 payment
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $19,784 1 payment
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents $8,500 1 payment
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression $274 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.